Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: Targets for treatment

William Rengifo-Cam, Pomila Singh

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Accumulating evidence in literature suggests that amidated and non-amidated gastrins (gastrin precursors) may play an important role in the proliferation and carcinogenesis of gastrointestinal and pancreatic cancers, especially in the presence of DNA damaging agents and/or infectious agents. Amidated gastrins appear to have a protective role, while progastrins exert growth promoting effects in cancers. Several receptor subtypes and signal transduction pathways mediate the biological effects of the gastrin peptides. Progastrin and gastrins also exert anti-apoptotic effects, which may additionally contribute to the growth and co-carcinogenic effects of these peptides on GI mucosal cells in vivo. Amidated gastrins additionally play an important role in the migration of GI epithelial cells, and in glandular morphogenesis, while progastrins may play an important role in invasion and metastasis. Therefore, targeting progastrins, gastrins, and their cognate receptors may provide a therapeutic tool for treating GI and pancreatic cancers. Targeting CCK2-receptors has, so far, not provided optimal beneficial effects. However, targeting gastrins via a vaccine approach has provided some encouraging results for treating GI and pancreatic cancers. It is expected that targeting precursor gastrins (progastrins and gly-gastrins), exclusively rather than amidated gastrins, may be more effective for treating GI cancers. Since GI cancers at advanced stages are largely responsive to autocrine and intracrine progastrins, down-regulation of intracellular progastrins will likely be more effective at this stage.

Original languageEnglish (US)
Pages (from-to)2345-2358
Number of pages14
JournalCurrent Pharmaceutical Design
Volume10
Issue number19
DOIs
StatePublished - 2004

Fingerprint

Cholecystokinin B Receptor
Gastrins
Pancreatic Neoplasms
big gastrin
Neoplasms
Peptides
Gastrointestinal Neoplasms
Growth
Morphogenesis
Signal Transduction
Carcinogenesis
Down-Regulation
Vaccines

Keywords

  • CCK-2 receptor
  • Colon carcinogenesis
  • Gastric cancers
  • Gastrin gene expression
  • Progastrin receptor
  • Signaling
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Role of progastrins and gastrins and their receptors in GI and pancreatic cancers : Targets for treatment. / Rengifo-Cam, William; Singh, Pomila.

In: Current Pharmaceutical Design, Vol. 10, No. 19, 2004, p. 2345-2358.

Research output: Contribution to journalArticle

@article{911653b31b8f46f895c9228bf93d6e47,
title = "Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: Targets for treatment",
abstract = "Accumulating evidence in literature suggests that amidated and non-amidated gastrins (gastrin precursors) may play an important role in the proliferation and carcinogenesis of gastrointestinal and pancreatic cancers, especially in the presence of DNA damaging agents and/or infectious agents. Amidated gastrins appear to have a protective role, while progastrins exert growth promoting effects in cancers. Several receptor subtypes and signal transduction pathways mediate the biological effects of the gastrin peptides. Progastrin and gastrins also exert anti-apoptotic effects, which may additionally contribute to the growth and co-carcinogenic effects of these peptides on GI mucosal cells in vivo. Amidated gastrins additionally play an important role in the migration of GI epithelial cells, and in glandular morphogenesis, while progastrins may play an important role in invasion and metastasis. Therefore, targeting progastrins, gastrins, and their cognate receptors may provide a therapeutic tool for treating GI and pancreatic cancers. Targeting CCK2-receptors has, so far, not provided optimal beneficial effects. However, targeting gastrins via a vaccine approach has provided some encouraging results for treating GI and pancreatic cancers. It is expected that targeting precursor gastrins (progastrins and gly-gastrins), exclusively rather than amidated gastrins, may be more effective for treating GI cancers. Since GI cancers at advanced stages are largely responsive to autocrine and intracrine progastrins, down-regulation of intracellular progastrins will likely be more effective at this stage.",
keywords = "CCK-2 receptor, Colon carcinogenesis, Gastric cancers, Gastrin gene expression, Progastrin receptor, Signaling, Vaccines",
author = "William Rengifo-Cam and Pomila Singh",
year = "2004",
doi = "10.2174/1381612043383999",
language = "English (US)",
volume = "10",
pages = "2345--2358",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "19",

}

TY - JOUR

T1 - Role of progastrins and gastrins and their receptors in GI and pancreatic cancers

T2 - Targets for treatment

AU - Rengifo-Cam, William

AU - Singh, Pomila

PY - 2004

Y1 - 2004

N2 - Accumulating evidence in literature suggests that amidated and non-amidated gastrins (gastrin precursors) may play an important role in the proliferation and carcinogenesis of gastrointestinal and pancreatic cancers, especially in the presence of DNA damaging agents and/or infectious agents. Amidated gastrins appear to have a protective role, while progastrins exert growth promoting effects in cancers. Several receptor subtypes and signal transduction pathways mediate the biological effects of the gastrin peptides. Progastrin and gastrins also exert anti-apoptotic effects, which may additionally contribute to the growth and co-carcinogenic effects of these peptides on GI mucosal cells in vivo. Amidated gastrins additionally play an important role in the migration of GI epithelial cells, and in glandular morphogenesis, while progastrins may play an important role in invasion and metastasis. Therefore, targeting progastrins, gastrins, and their cognate receptors may provide a therapeutic tool for treating GI and pancreatic cancers. Targeting CCK2-receptors has, so far, not provided optimal beneficial effects. However, targeting gastrins via a vaccine approach has provided some encouraging results for treating GI and pancreatic cancers. It is expected that targeting precursor gastrins (progastrins and gly-gastrins), exclusively rather than amidated gastrins, may be more effective for treating GI cancers. Since GI cancers at advanced stages are largely responsive to autocrine and intracrine progastrins, down-regulation of intracellular progastrins will likely be more effective at this stage.

AB - Accumulating evidence in literature suggests that amidated and non-amidated gastrins (gastrin precursors) may play an important role in the proliferation and carcinogenesis of gastrointestinal and pancreatic cancers, especially in the presence of DNA damaging agents and/or infectious agents. Amidated gastrins appear to have a protective role, while progastrins exert growth promoting effects in cancers. Several receptor subtypes and signal transduction pathways mediate the biological effects of the gastrin peptides. Progastrin and gastrins also exert anti-apoptotic effects, which may additionally contribute to the growth and co-carcinogenic effects of these peptides on GI mucosal cells in vivo. Amidated gastrins additionally play an important role in the migration of GI epithelial cells, and in glandular morphogenesis, while progastrins may play an important role in invasion and metastasis. Therefore, targeting progastrins, gastrins, and their cognate receptors may provide a therapeutic tool for treating GI and pancreatic cancers. Targeting CCK2-receptors has, so far, not provided optimal beneficial effects. However, targeting gastrins via a vaccine approach has provided some encouraging results for treating GI and pancreatic cancers. It is expected that targeting precursor gastrins (progastrins and gly-gastrins), exclusively rather than amidated gastrins, may be more effective for treating GI cancers. Since GI cancers at advanced stages are largely responsive to autocrine and intracrine progastrins, down-regulation of intracellular progastrins will likely be more effective at this stage.

KW - CCK-2 receptor

KW - Colon carcinogenesis

KW - Gastric cancers

KW - Gastrin gene expression

KW - Progastrin receptor

KW - Signaling

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=3042696851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042696851&partnerID=8YFLogxK

U2 - 10.2174/1381612043383999

DO - 10.2174/1381612043383999

M3 - Article

C2 - 15279613

AN - SCOPUS:3042696851

VL - 10

SP - 2345

EP - 2358

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 19

ER -